First-line therapy for these symptoms should focus on non-pharmacologic measures, followed by dopaminergic agonists (which also manage the motor symptoms of Parkinson’s disease) or cholinesterase inhibitors. The gene discussed is BCHE; the disease is Parkinson disease.